Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhitongzhu decoction is a Traditional Chinese Medicine (TCM) herbal formulation developed by the First Affiliated Hospital of Heilongjiang University of Chinese Medicine for the treatment of ankylosing spondylitis (AS). In the context of TCM, it is used to treat 'Bi syndrome' characterized by kidney deficiency and cold-dampness, aiming to alleviate spinal pain, reduce joint stiffness, and improve physical mobility. The therapeutic mechanism of the decoction involves immunomodulatory and anti-inflammatory actions, specifically by suppressing the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). It is typically administered as an oral liquid and is utilized as a specialized hospital preparation in clinical practice in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhitongzhu decoction.